Tourette Syndrome - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Tourette Syndrome - Pipeline Review, H2 2016

Tourette Syndrome - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Tourette Syndrome - Pipeline Review, H2 2016
Published Jul 20, 2016
71 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Tourette Syndrome - Pipeline Review, H2 2016, provides an overview of the Tourette Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tourette Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome
- The report reviews pipeline therapeutics for Tourette Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Tourette Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Tourette Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Tourette Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Tourette Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tourette Syndrome pipeline depth and focus of Indication th

  
Source:
Document ID
GMDHC8263IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Tourette Syndrome Overview71
Therapeutics Development81
  Pipeline Products for Tourette Syndrome Overview81
Tourette Syndrome Therapeutics under Development by Companies91
Tourette Syndrome Pipeline Products Glance103
  Clinical Stage Products101
  Early Stage Products111
  Unknown Stage Products121
Tourette Syndrome Products under Development by Companies131
Tourette Syndrome Companies Involved in Therapeutics Development147
  Catalyst Pharmaceuticals, Inc.141
  Neurocrine Biosciences, Inc.151
  Psyadon Pharmaceuticals, Inc.161
  Reviva Pharmaceuticals Inc.171
  Synchroneuron Inc.181
  Teva Pharmaceutical Industries Ltd.191
  Therapix Biosciences Ltd201
Tourette Syndrome Therapeutics Assessment219
  Assessment by Monotherapy Products211
  Assessment by Combination Products221
  Assessment by Target232
  Assessment by Mechanism of Action252
  Assessment by Route of Administration272
  Assessment by Molecule Type291
Drug Profiles3028
  (amfetamine + guanfacine hydrochloride) Drug Profile301
  acamprosate calcium SR Drug Profile312
  CPP-115 Drug Profile334
  deutetrabenazine ER Drug Profile375
  dronabinol + palmidrol Drug Profile421
  ecopipam hydrochloride Drug Profile433
  RP-5063 Drug Profile462
  valbenazine tosylate Drug Profile485
  vigabatrin Drug Profile535
Tourette Syndrome Dormant Projects581
Tourette Syndrome Discontinued Products591
Tourette Syndrome Product Development Milestones6010
  Featured News &Press Releases601
    Jun 15, 2016: Therapix Biosciences Filed an Application with the FDA to Approve an Orphan Designation for the Drug Developed Based on the Entourage Technology for Treating Tourettes Syndrome601
    Feb 03, 2016: Psyadon Announces Positive Independent Review of Phase 2b Study of Ecopipam for the Treatment of Tourette Syndrome in Children601
    Feb 02, 2016: Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome611
    Dec 16, 2015: Catalyst Pharmaceuticals Announces Top-Line Results in Phase 1(b) Trial of CPP-115621
    Dec 16, 2015: Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome621
    Oct 20, 2015: Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome631
    Jan 14, 2015: Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Tourette Syndrome in the Pediatric Population641
    Nov 24, 2014: Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by Treating Patients With CPP-115641
    Oct 02, 2014: Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study651
    May 28, 2014: Psyadon Announces the Opening of a New Clinical Trial of Ecopipam for the Treatment of Tourette Syndrome in Children Ages 7-17651
    Jul 24, 2012: Psyadon Announces Positive Interim Analysis Of Phase II Study Of Ecopipam For Treatment Of Tourette Syndrome661
    Feb 09, 2012: Catalyst Files Provisional Patent Application For GABA Aminotransferase Inhibitor CPP-115 In Treatment Of Tourette Syndrome671
    Sep 19, 2011: Neurocrine Biosciences Initiates Phase II Clinical Trial Of NBI-98854681
    May 11, 2011: Tourette Syndrome Association And Psyadon Pharma To Collaborate On Drug Trial For Tourette Syndrome Treatment681
    Apr 13, 2010: Neurocrine Biosciences Begins Second VMAT2 Phase I Clinical Trial691
Appendix702
  Methodology701
  Coverage701
  Secondary Research701
  Primary Research701
  Expert Panel Validation701
  Contact Us701
  Disclaimer711

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Tourette Syndrome - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Tourette-Syndrome-Pipeline-Review-H2-2016-2088-16237>
  
APA:
Global Markets Direct - Market Research. (2016). Tourette Syndrome - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Tourette-Syndrome-Pipeline-Review-H2-2016-2088-16237>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.